ImmunoBiology Ltd (“ImmBio”) was founded by Dr Camilo Colaco in 1999. Based on his insights as to how the immune system operates in biological systems ImmBio was established to develop products.

With seed corn funding and a UK Department of Trade and Industry (DTI) SMART Feasibility award, work was initiated at the UK’s National Institute of Standards & Control (NIBSC) on TB - both vaccination and therapy - and at the Elizabeth Macarthur Institute in New South Wales, Australia, studying the utility of the approach by measuring transmission for pestivirus.

With a further DTI SMART Development award and a funding round which broadened the investor base, an influenza programme was initiated. In collaboration with Reading University, a number of constructs were generated, analysed in ImmBio’s facilities, followed by challenge studies conducted at Retroscreen (a spin out from Queen Mary College, London) and NIBSC.

At the end of 2005, a Series C funding round and a collaborative agreement with Aeras for TB has put ImmBio into a solid position to further progress its portfolio into clinical studies.

A sister company, ImmBio Therapeutics was established in 2006, with the assistance of an East of England Development Agency award, to utilize the HspC technology for therapeutic targets, mediated through monoclonal antibodies (mAbs).